反応式
Cl.[Cl:2][C:3]1[N:8]=[C:7]([NH:9][CH2:10][CH2:11][C:12]2[CH:17]=[CH:16][CH:15]=[C:14]([CH2:18][N:19]([CH3:21])[CH3:20])[CH:13]=2)[C:6](=[O:22])[N:5]([CH2:23][C:24]([OH:26])=O)[C:4]=1[CH3:27].[NH:28]1[C:36]2[C:31](=[CH:32][C:33]([CH2:37][NH2:38])=[CH:34][CH:35]=2)[CH:30]=[CH:29]1>>[Cl:2][C:3]1[N:8]=[C:7]([NH:9][CH2:10][CH2:11][C:12]2[CH:17]=[CH:16][CH:15]=[C:14]([CH2:18][N:19]([CH3:20])[CH3:21])[CH:13]=2)[C:6](=[O:22])[N:5]([CH2:23][C:24]([NH:38][CH2:37][C:33]2[CH:32]=[C:31]3[C:36](=[CH:35][CH:34]=2)[NH:28][CH:29]=[CH:30]3)=[O:26])[C:4]=1[CH3:27]参加物
3
反応物 2
生成物 1
実験手順
The title compound was prepared by a similar method to preparation 9 from 2-[3-chloro-5-(3-[(dimethylamino)methyl]phenethylamino)-2-methyl-6-oxo-1(6H)-pyrazinyl]acetic acid hydrochloride (preparation 22) (85 mg, 0.20 mmol) and 1H-indol-5-ylmethylamine (preparation 8) (35 mg, 0.24 mmol) to give the title compound (100 mg, 0.19 mmol, 98%). 1H NMR (CD3OD) δ 2.20 (s, 3H), 2.70 (s, 6H), 3.00 (m, 2H), 3.60 (m, 2H), 4.20 (s, 2H), 4.50 (s, 2H), 4.80 (m, 2H), 7.05 (m, 1H), 7.10-7.55 (m, 9H), 7.75 (m, 1H), 7.85 (m, 1H). LRMS m/z=507.3, 509.3 (M+1)+.
出典と根拠
- ORDレコード
- ord-97045561a15b48c5a1c5f031fee40668
- 出典データセット
- uspto-grants-2001_01
- 特許番号
- US06180627B2
関連ノート
読み込み中…